These days it’s nearly impossible to turn around in the biopharma world without hearing about how some company is going to use machine learning to revolutionize drug development. “It really is a catchphrase,” acknowledged Jo Viney, whose latest startup, Seismic Therapeutic Inc. launched with a $101 million series A round to advance a platform incorporating machine learning capabilities to find new drugs for autoimmune diseases.

Congruence Therapeutics Inc. has closed on a $50 million series A financing to design small molecules to treat rare diseases with protein misfolding. Montreal-based Congruence uses structural bioinformatics, computational chemistry and machine learning in its in silico platform that detects key biophysical features on proteins. That data are used to then design drugs.

Cancer diagnostics company Biofidelity Ltd. reported a $23 million series A+ investment round, led by Octopus Ventures with participation from SBI Investment Co. Ltd. and existing investors. Funds will be used for the commercial launch of the company’s first commercial assay Asypre-Lung. The oncology panel is designed to detect DNA mutations from tissue or liquid biopsy quicker than current approaches like gene sequencing.

The G protein-coupled receptor (GPCR) is a foundational building block of modern medicine. While nearly everyone has taken one sometime in the past few decades, development has greatly slowed. With a fundraiser in hand, Septerna Inc. is looking at new ways of working around and through old problems.

LONDON – Cytovation AS has raised $20 million in a series A, enabling it to expand the monotherapy arm of a phase I/II trial of its tumor membrane immunotherapy, Cypep-1, and to test it in three combination arms with the checkpoint inhibitor Keytruda (pembrolizumab).

LONDON – Engitix Therapeutics Ltd. has raised $54 million in a series A round to advance early programs arising from its human extracellular matrix (ECM) target discovery platform towards the clinic with the support of new partner and equity investor Dompé Farmaceutici SpA.

PARIS – Healshape SAS is preparing a $6.8 million series A round to develop a 3D bioprinted breast implant obtained from the patients' own cells. Supported by Pulsalys SAS, Lyon Saint-Etienne’s technology transfer acceleration company, this startup from Villeurbanne, France, has already benefited from more than a million dollars of French public funding and subsidies.

Point-of-care (POC) diagnostics startup Chronus Health Inc. reeled in $22 million in a series A round led by Tarsadia Investments. The company plans to use the funds to scale its research, engineering and data science teams and hasten product and technology development. Monta Vista Capital, Sosv and Savantus Ventures also participated in the financings, along with an unidentified strategic investor.

Canadian company Future Fertility Inc. is hatching plans to expand the user base for its flagship egg prediction software product, Violet, for egg cryopreservation. The noninvasive image analysis tool uses artificial intelligence (AI) to evaluate the reproductive potential of mature eggs. Investors are backing the Toronto-based company with $6 million in series A funds, so it can expand internationally and develop additional assessment products.